美晨生態(300237.SZ):擬申請非公開發行不超15億元公司債券
格隆匯1月3日丨美晨生態(300237.SZ)公佈,根據公司業務發展需要,為拓寬公司融資渠道、優化公司融資結構,公司擬申請非公開發行規模為不超過人民幣15億元(含)的公司債券。
期限為不超過5年(含5年),可以為單一期限品種或多種期限的混合品種。此次債券的具體期限構成和各期限品種的發行規模提請公司股東大會授權董事會及董事會獲授權人士在發行前根據市場情況和公司資金需求情況,在上述範圍內確定。
募集資金擬用於償還2022年到期公司債券和補充流動資金。具體募集資金用途提請股東大會授權董事會或董事會授權人士根據公司資金需求情況和公司財務結構確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.